Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Clerico M, et al. Among authors: de mercanti sf. Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Expert Opin Drug Saf. 2017. PMID: 28641055 Free article. Review.
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group. Durelli L, et al. Among authors: de mercanti s. Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781. Expert Opin Biol Ther. 2009. PMID: 19278300 Clinical Trial.
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: de mercanti sf. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M. De Mercanti SF, et al. J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6. J Neurol Sci. 2021. PMID: 33770708
37 results